

	2015 11 19
	2015 11 19 2035 11 18
	58,166.57
/	91310000MA1K32KU1N

211

302 368

	2017	2016	2015
	44,993.32	45,753.08	40,654.64
	16,911.96	18,667.65	15,960.13
	5,238.11	1,093.36	5,575.99
	5,473.11	1,213.46	5,957.46
	3,779.89	3,083.87	4,838.62
	62.41%	59.20%	60.74%

OriGene Technologies, Inc.

100%

100%

/

/

100%

2015 2016 2017

100%

2015 2016 2017

100%

100%

1 /

		2017	2016	2015
BHB		12,708,377.34	5,386,352.27	-
	-	12,708,377.34	5,386,352.27	-

2 /

		2017	2016	2015
BioCheck		3,405,406.25	-	-
		3,405,406.25	-	-

3

		2017	2016	2015
ETP	BioCheck	27,107,033.75	-	-
BH Biotech, LLC	BHB	-	9,985,300.00	-
	-	27,107,033.75	9,985,300.00	-

4

1

NetSuite

/

0 90

12

2

NetSuite

IT

NetSuite

1

1

	2017	2016	2015
	44,993.32	45,753.08	40,654.64
	18,563.43	17,597.14	16,318.41
	41.26%	38.46%	40.14%
	9,926.58	10,951.19	8,862.61
	22.06%	23.94%	21.80%
	63.32%	62.40%	61.94%

2

	2017	2016	2015
	12,179.52	10,566.84	9,090.19
	5,842.74	4,705.74	3,922.38
	47.97%	44.53%	43.15%
	4,377.56	4,157.34	3,204.75
	35.94%	39.34%	35.26%
	83.91%	83.87%	78.41%

2

1

2

58

	2017	2016	2015
	10,006.34	9,314.09	7,798.41
	22.24%	20.36%	19.18%
	3,037.24	2,965.33	2,368.57
	24.94%	28.06%	26.06%

3

0 60

12

		2018 4 30		
2017 12 31	12,179.52	6,799.01	55.82%	3.68%
2016 12 31	10,566.84	10,467.09	99.06%	3.84%
2015 12 31	9,090.19	8,894.49	97.85%	2.36%

1

NetSuite ERP

IT

IT

NetSuite

2

NetSuite

IT

NetSuite

1

BHB

BHB

2

3

1

	2017	2016	2015
	13,883.49	14,757.00	12,426.36
	5,011.23	4,418.18	3,423.64
	36.09%	29.94%	27.55%
	3,482.90	4,624.60	4,088.29
	25.09%	31.34%	32.90%
	61.18%	61.28%	60.45%

	2017	2016	2015
	981.49	1,842.14	1,926.07
	318.06	758.89	467.61
	32.41%	41.20%	24.28%
	287.45	411.17	702.86
	29.29%	22.32%	36.49%
	61.70%	63.52%	60.77%

	2017	2016	2015
	70.75%	68.37%	72.76%
	57.88%	53.20%	53.31%
	62.41%	59.20%	60.74%

●

	2017	2016	2015
R&D Systems	66.53%	67.46%	67.94%
Abcam	70.06%	70.21%	70.49%
Thermo Fisher	45.15%	45.80%	45.72%
	60.58%	61.16%	61.38%
	70.75%	68.37%	72.76%

●

	2017	2016	2015
	41.31%	41.71%	42.15%
	67.49%	71.98%	72.77%
	72.04%	68.46%	72.14%
	60.28%	60.72%	62.35%
	57.88%	53.20%	53.31%



九、核查结论

会计师已实施了有效的核查程序，核查范围充分。通过实施上述核查程序及获取的相关证据，会计师认为，上海傲源 2015 年度、2016 年度、2017 年度的业绩真实、可靠。

